Acumen Pharmaceuticals Inc (ABOS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.21-1.16%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ABOS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Based on the initial topline results, Acumen plans to cease development of sabirnetug, including the open-label extension portion of the ALTITUDE-AD trial, and to evaluate its strategic options, incl…
Stated in 1 of 3 supplied quarters. Management reported: “Based on the initial topline results, Acumen plans to cease development of sabirnetug, including the open-label extension portion of the ALTITUDE-AD trial, and to evaluate its strategic options, including its Enhanced Brain Delivery™ (EBD®) program.” “In the interim, the Company plans to take steps to implement cash conservation measures and explore strategic options to maximize shareholder value.” Operating income was $-25.813 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Based on the initial topline results, Acumen plans to cease development of sabirnetug, including the open-label extension portion of the ALTITUDE-AD trial, and to evaluate its strategic options, incl…”
We continue to advance IND-enabling activities toward a mid-2027 IND submission for a lead candidate, and are excited about the optionality this innovative product approach adds to our pipeline and t…
Stated in 2 of 3 supplied quarters. Management reported: “We continue to advance IND-enabling activities toward a mid-2027 IND submission for a lead candidate, and are excited about the optionality this innovative product approach adds to our pipeline and the potential it holds to deliver a next-generation treatment for AD.”” “We are advancing IND-enabling activities toward a mid-2027 IND submission and are excited about the potential to offer patients and caregivers more effective and convenient therapeutic options.””
“We continue to advance IND-enabling activities toward a mid-2027 IND submission for a lead candidate, and are excited about the optionality this innovative product approach adds to our pipeline and t…”
“• The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.”
Cash is expected to support current clinical and operational activities into early 2027.
Stated in 2 of 3 supplied quarters. Management reported: “Cash is expected to support current clinical and operational activities into early 2027.” “Cash is expected to support current clinical and operational activities into early 2027.”
“Cash is expected to support current clinical and operational activities into early 2027.”
“Cash is expected to support current clinical and operational activities into early 2027.”
Develop the EBD program with JCR, including nominated candidates and IND-enabling work toward a lead-candidate filing targeted for mid-2027.
Complete the Phase 2 ALTITUDE-AD readout for sabirnetug in early Alzheimer's disease, a milestone management had scheduled for late 2026.
Over the trailing year it converted 1.04x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.